Author: Ravi Shankar

Vilnius, Lithuania, Oct. 22, 2026 (GLOBE NEWSWIRE) —

UAB Janonio 27, a company managed by the investment company AB Tewox, has successfully completed the construction of a grocery store located at J. Janonio St. 27, Klaipeda. The total investment in the project amounts to approximately EUR 6.5 million.

The property is leased on a long-term basis to the supermarket chain Lidl, which starts operations in the newly developed premises on 22 October 2026. The total leasable area is approximately 2,100 sq. m.

One additional store will be built in Lithuania in 2026. In total, more than 10,000 sq. m of leasable area will be developed this year.

Contact person for further information:

Paulius Nevinskas
Manager of the Investment Company
paulius.nevinskas@lordslb.lt
https://lordslb.lt/tewox_bonds/

New FI-3000 FiberInspector Pro MMC inspection tips provide access to hard-to-reach connections, eliminating the need to disconnect multiple fibres to gain access

Eindhoven, Netherlands, Oct. 22, 2026 (GLOBE NEWSWIRE) — As AI, cloud and high-speed networking drive higher fibre density in data centres, technicians installing or troubleshooting fibre connections need to inspect connector end faces hidden within densely populated patch panels. The process increases troubleshooting time, operational complexity and the risk of network disruption. To address these challenges, Fluke Networks today announced new inspection tips for the FI-3000 FiberInspector™ Pro, enabling access to MMC fibre connections in high-density environments without disturbing critical network infrastructure.

The new portfolio consists of two MMCE extended-reach inspection tips, available in keyed and keyless versions, that eliminate one of the most common challenges in high-density data centres: accessing fibre connectors for inspection without disturbing active infrastructure. The tips provide direct access to bulkhead connectors and patch panel ports from the front of the rack, reducing the need to disconnect multiple fibre assemblies while accelerating troubleshooting and helping protect network uptime.

Contaminated fibre remains one of the leading causes of optical network performance issues. In an NTT-Advanced Technology study, 96% of installers and 80% of network operators reported problems related to connector end-face contamination. As connector density increases, so does the challenge of inspecting and maintaining fibre connections. Multi-fibre connectors create more opportunities for contamination while making access and inspection more difficult. The new MMC inspection tips help technicians follow fibre inspection best practices, inspect hard-to-reach connectors and maintain fibre quality without adding workflow complexity.

“The industry’s push toward greater fibre density is transforming data centre infrastructure, but it’s also creating new challenges for the teams responsible for keeping networks running reliably,” said Mark Mullins, Global Product Manager, Fluke Networks. “Technicians shouldn’t have to disrupt installed infrastructure just to inspect a fibre connection. With these new FI-3000 inspection tips, we’re removing a longstanding operational tradeoff by enabling access to hard-to-reach MMC connectors from the front of the rack. That means faster installation and troubleshooting, less complexity and greater confidence that critical networks remain online and performing as expected.”

Together, the new inspection tips help reduce the operational burden associated with maintaining and troubleshooting fibre infrastructure. Rather than disconnecting adjacent connections to gain access or spending time locating the correct fibre from the back of a rack, technicians can inspect connectors directly through the front of populated patch panels. This streamlined workflow helps accelerate commissioning, troubleshooting and routine maintenance activities.

The MMC tips are designed for use with the FI-3000 FiberInspector Ultra, part of Versiv™, the industry’s leading Cabling Certification platform, which also supports twisted pair cabling along with single-and multifibre connections.  Contractors using the platform report minimal training time and Fluke offers factory-certified training with over 10,000 certified technicians worldwide. Documentation of results is offered through LinkWare™, the most widely accepted reporting software with nearly 40,000 downloads and nearly 200 million results stored.

To learn more about the new MMC inspection tips for the FI-3000 FiberInspector Pro and how they simplify inspection of critical fibre connections in high-density data centre environments, please visit FI-3000 FiberInspector Pro MMC Inspection Tips.

About Fluke
Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measurement and condition monitoring. Fluke customers include technicians, engineers, electricians, maintenance managers and metrologists who install, troubleshoot and maintain industrial, electrical and electronic equipment and calibration processes.

###

FLUKE is a registered trademark of Fluke Corporation. For more information, visit www.fluke.com.

Media Contacts:
Dave Smith
Fluke Corporation
dave.smith@fluke.com

Olivia Kline
Fluke Corporation
olivia.kline@fluke.com

Q: What is the FI-3000 FiberInspector™ Pro?
A: The FI-3000 FiberInspector™ Pro is a fiber inspection solution that helps technicians identify contamination and defects on fibre connector end faces before they impact network performance, reliability or certification results. Automated pass/fail analysis and interchangeable inspection tips enable fast, consistent inspection across a wide range of fiber connector types.

Q: What challenges are the new FI-3000 FiberInspector™ Pro tips designed to address?
A: As data centres increase fiber density to support AI, cloud and high-speed networking, technicians often have to disconnect multiple fibre connections or work through crowded racks to access connectors for inspection. The new inspection tips provide direct access to hard-to-reach MMC connectors, reducing complexity, troubleshooting time and the risk of network disruption.

Q: What benefits do the new FI-3000 inspection tips deliver to customers?
A: The new tips make it easier to inspect critical fibre connections without disconnecting active infrastructure. Customers can accelerate maintenance and troubleshooting, improve adherence to fibre inspection best practices, maintain fibre quality and help protect network reliability and uptime.

 

Attachments

• New Fluke FI-3000 FiberInspector Pro MMC inspection tips provide access to hard-to-reach connections
• New Fluke FI-3000 FiberInspector Pro MMC inspection tips provide access to hard-to-reach connections

CONTACT: Olivia Kline
Fluke Corporation
olivia.kline@fluke.com

23, Place des Carmes-Déchaux – 63000 CLERMONT-FERRAND

Information about securities repurchasing program
Regulated information
Issuer social denomination: Michelin – LEI 549300SOSI58J6VIW052
Types of securities: ordinary shares – Code ISIN FR001400AJ45
Date : October 22nd, 2026

Issuer Name	Issuer code	Transaction date	ISIN Code	Daily total volume (in number of actions)	Daily weighted average price of shares acquired	Platform
Compagnie Générale des Etablissements Michelin	549300SOSI58J6VIW052	22.10.2026	FR001400AJ45	201 143	32,5366 euros	Over-the-counter
Compagnie Générale des Etablissements Michelin	549300SOSI58J6VIW052	22.10.2026	FR001400AJ45	201 143	32,5366 euros	Over-the-counter
Compagnie Générale des Etablissements Michelin	549300SOSI58J6VIW052	22.10.2026	FR001400AJ45	201 143	32,5366 euros	Over-the-counter

Issuer Name	Issuer code	PSI Name	Issuer Code	Transaction date	ISIN Code	Unit Price	Currency	Quantity bought	Platform	Transaction reference number	Buyback objective
Compagnie Générale des Etablissements Michelin	549300SOSI58J6VIW052	NATIXIS	KX1WK48MPD4Y2NCUIZ63	22.10.2026	FR001400AJ45	32,5366	Euro	201 143	Over-the-counter	5309224	Cancellation
Compagnie Générale des Etablissements Michelin	549300SOSI58J6VIW052	BNP PARIBAS	R0MUWSFPU8MPRO8K5P83	22.10.2026	FR001400AJ45	32,5366	Euro	201 143	Over-the-counter	5309224	Cancellation
Compagnie Générale des Etablissements Michelin	549300SOSI58J6VIW052	SOCIETE GENERALE	O2RNE8IBXP4R0TD8PU41	22.10.2026	FR001400AJ45	32,5366	Euro	201 143	Over-the-counter	5309224	Cancellation

Attachment

• 20261022 – Disclosure of trading in own shares – October 22nd, 2026

Winterthur, Switzerland / Shenyang, China, 22. October 2026 – Shenyang Yuanda Compressor Co., Ltd. (SYCC), a subsidiary of Burckhardt Compression, has secured several orders for diaphragm compressor units supporting hydrogen applications in the semiconductor industry. The projects will serve semiconductor manufacturing facilities in Taiwan and Korea through a leading global industrial gas supplier.

The compressor units will boost hydrogen pressure downstream of a purification system, enabling the reliable delivery of ultra-high-purity hydrogen required for advanced semiconductor manufacturing processes.

Hydrogen plays a critical role in semiconductor production. It is used in key manufacturing steps such as epitaxial growth, annealing, deposition and advanced lithography processes, helping chip manufacturers maintain the extremely high levels of purity and precision required for today’s semiconductors.

Driven by continued investments in artificial intelligence, data centers, advanced electronics and digital infrastructure, semiconductor manufacturers around the world are expanding production capacity. This growth is increasing demand for ultra-high-purity process gases and the associated compression technologies required throughout the semiconductor value chain.

Leveraging Burckhardt Compression’s proven piston and gas-tight diaphragm compressor technologies, SYCC provides robust hydrogen compression solutions, designed to meet the stringent purity, safety and reliability requirements of semiconductor manufacturing facilities.

These orders further strengthen Burckhardt Compression’s position in hydrogen compression and provide an entry into a new market for the company, based on its existing technology portfolio.

CHICAGO, Oct. 22, 2026 (GLOBE NEWSWIRE) — Marquette National Corporation (OTCQX: MNAT) today announced that its Board of Directors declared a cash dividend of $0.33 per share. The dividend will be payable on January 4, 2027 to shareholders of record on December 18, 2026. As of September 30, 2026, Marquette had 4,388,274 shares issued and outstanding.  

The Company also announced that its Board of Directors authorized the repurchase of up to $1,000,000 of its outstanding common stock at prevailing market prices through open market or negotiated transactions. The repurchase program is authorized from January 1, 2027 through December 31, 2027. The Company’s previously announced Repurchase Program will terminate on December 31, 2026.

Marquette National Corporation is a diversified bank holding company with total assets of $2.1 billion. The Company’s banking subsidiary, Marquette Bank, is a full-service, community bank that serves the financial needs of communities in Chicagoland, offering an extensive line of financial solutions, including retail banking, real estate lending, trust, insurance, investments, wealth management and business banking to consumers and commercial customers. Marquette Bank has 20 branches located in: Chicago, Bolingbrook, Bridgeview, Evergreen Park, Hickory Hills, Lemont, New Lenox, Oak Forest, Oak Lawn, Orland Park, Summit and Tinley Park, Illinois. For more information visit: https://emarquettebank.com

Special Note Concerning Forward-Looking Statements
This document contains, and future oral and written statements of the Company and its management may contain, forward-looking statements with respect to the financial condition, results of operations, plans, objectives, future performance and business of the Company. Forward-looking statements, which may be based upon beliefs, expectations and assumptions of the Company’s management and on information currently available to management, are generally identifiable by the use of words such as “believe,” “expect,” “anticipate,” “bode”, “predict,” “suggest,” “project”, “appear,” “plan,” “intend,” “estimate,” ”annualize,” “may,” “will,” “would,” “could,” “should,” “likely,” “might,” “potential,” “continue,” “annualized,” “target,” “outlook,” as well as the negative forms of those words, or other similar expressions. Additionally, all statements in this document, including forward-looking statements, speak only as of the date they are made, and the Company undertakes no obligation to update any statement in light of new information or future events. A number of factors, many of which are beyond the ability of the Company to control or predict, could cause actual results to differ materially from those in its forward-looking statements. These factors include, but are not limited to: (i) the strength of the local, state, national and international economies and financial markets (including effects of inflationary pressures); (ii) effects on the U.S. economy resulting from actions taken by the federal government, including the threat or implementation of tariffs, immigration enforcement, and changes in foreign policy and tax regulations; (iii) the economic impact of any future terrorist threats and attacks, widespread disease or pandemics, military conflicts, acts of war or threats thereof (including the Russian invasion of Ukraine, ongoing conflicts in the Middle East and the recent military actions in Venezuela), or other adverse events that could cause economic deterioration or instability in credit markets, and the response of the local, state and national governments to any such adverse external events; (iv) new or revised accounting policies and practices, as may be adopted by state and federal regulatory agencies, the Financial Accounting Standards Board or the Public Company Accounting Oversight Board; (v) changes in local, state and federal laws, regulations and governmental policies concerning the Company’s general business; (vi) the imposition of tariffs or other governmental policies impacting the value of products produced by the Company’s commercial borrowers; (vii) increased competition in the financial services sector, including from non-bank competitors such as credit unions and fintech companies, and the inability to attract new customers; (viii) changes in technology and the ability to develop and maintain secure and reliable electronic systems; (ix) unexpected results of acquisitions which may include failure to realize the anticipated benefits of the acquisitions and the possibility that transaction costs may be greater than anticipated; (x) the loss of key executives and employees, talent shortages and employee turnover; (xi) changes in consumer spending; (xii) unexpected outcomes and costs of existing or new litigation or other legal proceedings and regulatory actions involving the Company; (xiii) the economic impact on the Company and its customers of climate change, natural disasters and exceptional weather occurrences such as tornadoes, floods and blizzards; (xiv) fluctuations in the value of securities held in our securities portfolio, including as a result of changes in interest rates; (xv) credit risk and risks from concentrations (by type of borrower, geographic area, collateral and industry) within our loan portfolio and large loans to certain borrowers (including CRE loans); (xvi) the overall health of the local and national real estate market; (xvii) the ability to maintain an adequate level of allowance for credit losses on loans; (xviii) the concentration of large deposits from certain clients who have balances above current FDIC insurance limits and who may withdraw deposits to diversify their exposure; (xix) the ability to successfully manage liquidity risk, which may increase dependence on non-core funding sources such as brokered deposits, and may negatively impact the Company’s cost of funds; (xx) the level of non-performing assets on our balance sheets; (xxi) interruptions involving our information technology and communications systems or third-party servicers; (xxii) the occurrence of fraudulent activity, breaches or failures of our third-party vendors’ information security controls or cybersecurity-related incidents, including as a result of sophisticated attacks using artificial intelligence and similar tools or as a result of insider fraud; (xxiii) changes in the interest rates and repayment rates of the Company’s assets; (xxiv) the effectiveness of the Company’s risk management framework, and (xxv) the ability of the Company to manage the risks associated with the foregoing as well as anticipated. These risks and uncertainties should be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

For more information: Patrick Hunt SEVP / CFO 708-364-9019 phunt@emarquettebank.com

SSCP Lager BidCo AB (publ) (“SSCP Lager BidCo” or the “Issuer”), announced on 6 October 2026 that the Issuer is exercising its right to make a conditional voluntary total redemption of its outstanding senior secured floating rate notes 2023/2026 with ISIN SE0021021193 (the “Notes” and the “Redemption”), in accordance with the terms and conditions of the Notes.

The Redemption was conditional upon the successful execution of a facilities agreement with, inter alios, certain lenders and the Issuer being content that the conditions for utilisation of the facilities provided in the facilities agreement will be satisfied no later than on 30 October 2026, which is the date of the Redemption (the “Redemption Date” and the “Condition”).

SSCP Lager BidCo today announces that the Issuer successfully has executed the facilities agreement with, inter alios, certain lenders and is content that the conditions for utilisation of the facilities provided in the facilities agreement will be satisfied no later than on the Redemption Date. The Condition has therefore been satisfied, and the Redemption is no longer conditional and will consequently occur on the Redemption Date. The redemption price, together with accrued and unpaid interest, will be paid to each person who is registered as owner of Notes in the debt register maintained by Euroclear Nordics AB at end of business as per the record date on 23 October 2026.

Further information regarding the Redemption can be found in the Issuer’s press release published on 6 October 2026.

For further information, please contact:

Joel Engström, CEO, telephone number: +46 734 36 36 29, joel.engstrom@logent.se

Andrzej Kulik, CFO, telephone number: +46 738 15 67 00, andrzej.kulik@logent.se

About Logent Group
Logent is a comprehensive and independent logistics partner, with a Nordic base and with global networks. We have a wide range of services and create value for our customers through guaranteed cost and quality improvements. Our services include Logistics Services such as Warehouse Management, Transport Management and Customs, Port and Combined Terminals, Staffing Services and Consulting Services. This means that Logent has grown to a turnover of about SEK 3 billion from the start in 2006 and employs approximately 3,000 people.

see attached

Attachment

• OSB_ENG_Q32026 (1)

Correction: the updated Q3 2026 earnings release now includes Note 12. Everything else unchanged.  

OSLO, Norway (22 October 2026) – TGS today reports interim financial results for Q3 2026.

Financial highlights:

• Revenues of USD 397 million driven by high contract activity, compared to USD 388 million in Q3 2025 
• EBITDA of USD 222 million, including USD 41 million in gain from sale of the well data business, compared to USD 242 million in Q3 2025
• EBIT of USD 86 million, including USD 41 million in gain from sale of the well data business, compared to USD 94 million in Q3 2025
• Cost impacted by operational challenges 
• Robust order inflow¹ of USD 357 million resulting in a total order backlog¹ of USD 679 million, a Y/Y increase of 52%
• Dividend of USD 0.155 per share to be paid in Q4 2026

“The third quarter saw strong contract activity across both the 3D streamer vessel fleet and the Ocean Bottom Node (OBN) operations, resulting in the highest contract revenues since the fourth quarter of 2024. Although a higher activity level led to year-over-year growth in revenue, margins were negatively impacted by a combination of higher costs, driven by operational challenges, and low contract pricing. Going forward we are pleased to see a stronger pipeline of streamer contract opportunities, with clients competing for available capacity on several occasions. This development gives us confidence that contract pricing will improve from 2027. In OBN, tendering activity continues to increase, reinforcing our expectation of higher activity levels next year.

Our order intake continues to be strong, supported by a healthy mix of new contract awards and multi-client projects during the quarter, bringing total backlog to USD 679 million, up 52% from Q3 last year. The streamer fleet is fully booked for the fourth quarter, and visibility has improved significantly compared with the same period last year, enabling us to optimize asset allocation. Given the increased volume of contract work in the pipeline, we have decided to defer certain multi-client projects. As a result, we now expect multi-client investments in 2026 to be approximately USD 510 million, compared with our previous guidance of approximately USD 550 million.

Sustained high oil prices have strengthened our customers’ cash flows, while a marked increase in acreage awards has created a growing inventory of areas yet to be evaluated and explored. Together, these developments are driving demand for high-quality seismic data and reinforce our confidence in the opportunities ahead,” says Kristian Johansen, CEO of TGS.

Management presentation
CEO Kristian Johansen and CFO Sven Børre Larsen will present the results today at 09:00 a.m. CEST. The presentation will be webcasted live.

Webcast access and registration are available by copying and pasting the link below into your browser, or use the link on the front page of www.tgs.com:
https://qcnl.tv/p/F9pp7ArbItpZ5nPyrrIErw

The Q3 2026 earnings release and presentation will be available on www.tgs.com and www.newsweb.no.

For more information, visit TGS.com (http://www.tgs.com) or contact:

Bård Stenberg, VP IR & Business Intelligence
Mobile: +47 992 45 235
E-mail: investor@tgs.com

¹Order inflow and backlog excludes the North American well data business, which was sold in Q3 2026.

About TGS
TGS provides advanced data and intelligence to companies active in the energy sector. With leading-edge technology and solutions spanning the entire energy value chain, TGS offers a comprehensive range of insights to help clients make better decisions. Our broad range of products and advanced data technologies, coupled with a global, extensive and diverse energy data library, make TGS a trusted partner in supporting the exploration and production of energy resources worldwide. For further information, please visit www.tgs.com (https://www.tgs.com/).

Forward Looking Statement
All statements in this press release other than statements of historical fact are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that are difficult to predict and are based upon assumptions as to future events that may not prove accurate. These factors include volatile market conditions, investment opportunities in new and existing markets, demand for licensing of data within the energy industry, operational challenges, and reliance on a cyclical industry and principal customers. Actual results may differ materially from those expected or projected in the forward-looking statements. TGS undertakes no responsibility or obligation to update or alter forward-looking statements for any reason.

Attachments

• TGS Earnings Release Q3 2026
• Q3 2026 Presentation

Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo

Lower NfL and GFAP levels provide objective, complementary biological evidence of reduced neuroaxonal injury and suppressed reactive astrogliosis

Biomarker results support previously reported functional (LCVA) +18-letter gains and structural retinal preservation at Month 3, reinforcing Privosegtor’s development for acute optic neuritis and acute multiple sclerosis relapses

ZUG, Switzerland — October 22, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced new translational biomarker data from the Phase 2 ACUITY trial of Privosegtor in patients with optic neuritis (ON).

Increases in plasma neurofilament light chain (NfL) and plasma glial fibrillary acidic protein (GFAP) levels were reduced with Privosegtor vs placebo, particularly at early timepoints close to acute ON onset. Together with previously observed improvements in low-contrast visual acuity with 18-letter gains at Month 3 vs steroid alone, and preserved retinal structure, these findings provide convergent evidence across visual functional, retinal, and serum-based markers, further supporting the evaluation of Privosegtor as a potential neuroprotective therapy.

The late-breaking data were presented by Céline Louapre, M.D., Ph.D., of Pitié-Salpêtrière Hospital and Sorbonne University, during the 10th Joint ACTRIMS-ECTRIMS Meeting, MSToronto 2026.

The Phase 2 ACUITY biomarker analysis evaluated neurodegenerative markers in the blood to quantify structural neuroaxonal preservation and glial modulation following an acute episode of ON:

Neuroaxonal Preservation (LS mean change from baseline in plasma NfL levels,

This is demonstrated graphically in a figure in the attached PDF version of this press release.

At Day 5, the mean increase in plasma NfL was higher in the placebo group than in the Privosegtor group. NfL levels remained stable in the Privosegtor group through Month 6, whereas levels in the placebo group remained elevated above baseline at Month 1 before returning to baseline by Month 6. Lower NfL levels are consistent with reduced structural neuroaxonal injury along the optic nerve pathway.

Reactive Astrogliosis Reduction (LS mean change from baseline in plasma GFAP levels)

This is demonstrated graphically in a figure in the attached PDF version of this press release.

At Day 5, the mean increase in plasma GFAP was greater in the placebo group than in the Privosegtor group. GFAP levels remained elevated above baseline in the placebo group from Month 1 through Month 6, whereas they remained below baseline in the Privosegtor group over the same period. Lower plasma GFAP levels are consistent with reduced acute reactive astrocytic inflammation and reduction of the secondary neurodegenerative cascade.

Céline Louapre, M.D., Ph.D., Professor of Neurology at Pitié-Salpêtrière Hospital, Sorbonne University, and presenting author said: “These findings are particularly noteworthy because they provide biological evidence that complements the functional and retinal structural improvements previously observed in ACUITY. The consistent effects across NfL and GFAP suggest that Privosegtor may be influencing multiple pathways involved in tissue injury following acute optic neuritis, supporting its potential as a neuroprotective therapeutic approach. Together, these data deepen our understanding of the treatment’s effects and further support continued clinical evaluation.”

Riad Sherif, M.D., Chief Executive Officer of Oculis added: “For patients with optic neuritis, irreversible neuro-axonal damage can occur within days of disease onset, yet there are currently no approved therapies designed to protect retinal ganglion cells and their axons, the neurons responsible for transmitting visual signals from the eye to the brain, and preserve long-term visual function. These biomarker findings and translational analyses provide important additional evidence supporting Privosegtor’s neuroprotective potential, strengthening our confidence as we advance the PIONEER registrational program and explore its broader applicability across acute neuro-axonal conditions, including acute multiple sclerosis relapses.”

This Late-Breaker Abstracts poster presentation will be available under the Investors & Media section of the Oculis corporate website at www.oculis.com.

– Ends –

About Privosegtor
Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic and neuro-axonal diseases. Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improved visual function, corroborated by anatomical preservation of the retina, including the GCIPL and RNFL layers, and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Consistent results were observed in animal models of glaucoma, optic neuritis, and multiple sclerosis (MS), where Privosegtor preserved retinal ganglion cells and was associated with improvements in mobility (clinical function disability) in the MS model.

Privosegtor has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) as well as Orphan Drug designation from both the FDA and the EMA for ON. Privosegtor is currently being evaluated in Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON and one registrational trial in non-arteritic anterior ischemic optic neuropathy (NAION). Building on the ACUITY Phase 2 dataset in ON and constructive FDA pre-IND feedback, Oculis is also planning an IND submission for Privosegtor for the treatment of acute MS relapses.

Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country.

About Optic Neuritis
Optic Neuritis (ON) is a rare condition characterized by an acute inflammation of the optic nerve that can lead to permanent visual impairment. It affects up to 8 in 100,000 people worldwide with a U.S. annual incidence estimated to be >30,000 and often represents the first sign of multiple sclerosis^1,2. It mainly occurs in adults between 20 and 40 years of age and is more frequent in women (2:1)³. ON is a type of neuropathy (nerve disease) that happens when acute inflammation of the optic nerve affects the signals traveling from the eyes through the brain, causing pain, vision loss and other symptoms. The cells that make up the optic nerve have a lipid protective coating called a myelin sheath, which is preferentially damaged in ON. Without myelin, the optic nerve cells can’t send signals properly and axons can be irreversibly lost. To date there is no specific therapy approved for acute optic neuritis and the unmet need remains for therapies that can prevent vision loss after an acute episode by reducing permanent nerve cell damage or death.

About Acute Multiple Sclerosis (MS) Relapses
MS is a chronic immune-mediated disease affecting approximately 2.8 million people worldwide, including around 850,000 in the U.S. alone.^4-6 There are two main types of MS: relapsing-remitting MS (RRMS) and progressive MS. While progressive MS remains a significant unmet medical need, RRMS is the most common type, representing ~85% of patients at initial diagnosis.⁵ It is currently managed using immunomodulators or disease-modifying therapies (DMTs) that reduce the rate of relapses and therefore related relapse-associated worsening (RAW). However, relapses still persist for many patients, with an estimated 170,000 MS relapses occurring each year in the U.S.⁷

During an acute relapse, neurologists commonly use a short course of high-dose corticosteroids to reduce inflammation and shorten the episode, as is also standard of care in optic neuritis. However, corticosteroids do not influence the long-term disability, and recovery from relapses is often incomplete, such as in optic neuritis. The tissue damage that occurs during these relapses can contribute to neuroaxonal loss and the accumulation of functional disability over time, underscoring the need for therapies that protect neurons and axons during relapses. There are currently no neuroprotective therapies approved for MS relapses, and there remains an urgent unmet medical need for treatments that can prevent central nervous system damage.

About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial, and is being developed with a genotype-based approach for treating patients with TNFR1-mediated dry eye disease (DED). Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
           
For more information, please visit: www.oculis.com

Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

Media Relations
ICR Healthcare
Amber Fennell
oculis@icrhealthcare.com

Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the potential for Privosegtor to become the first neuroprotective therapy for optic neuritis and its potential broad applicability across neurology, including in acute MS relapses; the potential significance of biomarker data and analyses; the initiation, enrollment, timing, progress and results of current and future clinical trials; Oculis’ research and development programs; regulatory and business strategy; Oculis’ future development plans; the timing or likelihood of regulatory filings and approvals; and statements about market opportunity, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Results of earlier stage clinical trials may not be replicated in subsequent clinical trials. Statements regarding the potential significance of biomarker data are inherently uncertain, and observed biomarker changes may not be predictive of or correlate with favorable clinical outcomes. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (SEC). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

References:

1. Weidong Gu et al. Incidence of Optic Neuritis and the Associated Risk of Multiple Sclerosis for Service Members of U.S. Armed Forces, Military Medicine, vol. 188, March/April 2023
2. Abbass, N.J., Shaia, J.K., Shukla, P. et al. Prevalence of pediatric and adult optic neuritis in the United States from 2016 to 2023. Eye 39, 1608–1614 (2025).
3. Guier CP, Kaur K, Stokkermans TJ. Optic Neuritis. January 2025
4. MS National Society
5. Wallin et al., 2019, The prevalence of MS in the United States: A population-based estimate using health claims data – PubMed
6. McGinley et al., 2021, Diagnosis and Treatment of Multiple Sclerosis: A Review – PubMed
7. Multiple sources on relapse rate (ARR) including: Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study – PubMed

Attachment

• Oculis Holding AG – Press Release

Volta Finance Limited (VTA/VTAS)
Legal Entity Identification Code: 2138004N6QDNAZ2V3W80

Publication of the Annual Report and Audited Financial Statements
(the “Accounts”) for the financial year ended 31 July 2026

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION,
IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES

*****

Guernsey, 22 October 2026

Volta Finance Limited has published its results for the financial year ended 31 July 2026. The 2026 Accounts are attached to this release and will be available on the Volta Finance Limited website (www.voltafinance.com).

An xHTML version will be made available on the FCA’s national storage mechanism (NSM) in due course.

For further information, please contact:

Company Secretary and Administrator
BNP Paribas S.A., Guernsey Branch
guernsey.bp2s.volta.cosec@bnpparibas.com 
+44 (0) 1481 750 850

Corporate Broker
Cavendish Securities plc
Andrew Worne
Daniel Balabanoff
+44 (0) 20 7397 8900

For the Investment Manager
BNP Paribas Asset Management Europe

Matthieu Laurence
matthieu.laurence@axa-im.com
+33 (0) 1 44 45 88 82

*****

ABOUT VOLTA FINANCE LIMITED

Volta Finance Limited is incorporated in Guernsey under The Companies (Guernsey) Law, 2008 (as amended) and listed on Euronext Amsterdam and the London Stock Exchange’s Main Market for listed securities. Volta’s home member state for the purposes of the EU Transparency Directive is the Netherlands. As such, Volta is subject to regulation and supervision by the AFM, being the regulator for financial markets in the Netherlands.

Volta’s Investment objectives are to preserve its capital across the credit cycle and to provide a stable stream of income to its Shareholders through dividends that it expects to distribute on a quarterly basis. The Company currently seeks to achieve its investment objectives by pursuing exposure predominantly to CLO’s and similar asset classes. A more diversified investment strategy across structured finance assets may be pursued opportunistically. The Company has appointed BNP Paribas Asset Management Europe an investment management company with a division specialised in structured credit, for the investment management of all its assets.

*****

This press release is published by BNP Paribas Asset Management Europe (“BNPP AM”), in its capacity as alternative investment fund manager (within the meaning of Directive 2011/61/EU, the “AIFM Directive”) of Volta Finance Limited (the “Volta Finance”) whose portfolio is managed by BNPP AM.

This press release is for information only and does not constitute an invitation or inducement to acquire shares in Volta Finance. Its circulation may be prohibited in certain jurisdictions and no recipient may circulate copies of this document in breach of such limitations or restrictions. This document is not an offer for sale of the securities referred to herein in the United States or to persons who are “U.S. persons” for purposes of Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or otherwise in circumstances where such offer would be restricted by applicable law. Such securities may not be sold in the United States absent registration or an exemption from registration from the Securities Act. Volta Finance does not intend to register any portion of the offer of such securities in the United States or to conduct a public offering of such securities in the United States.

*****

This communication is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The securities referred to herein are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. Past performance cannot be relied on as a guide to future performance.

*****

This press release contains statements that are, or may deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “anticipated”, “expects”, “intends”, “is/are expected”, “may”, “will” or “should”. They include the statements regarding the level of the dividend, the current market context and its impact on the long-term return of Volta Finance’s investments. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Volta Finance’s actual results, portfolio composition and performance may differ materially from the impression created by the forward-looking statements. BNPP AM does not undertake any obligation to publicly update or revise forward-looking statements.

Any target information is based on certain assumptions as to future events which may not prove to be realised. Due to the uncertainty surrounding these future events, the targets are not intended to be and should not be regarded as profits or earnings or any other type of forecasts. There can be no assurance that any of these targets will be achieved. In addition, no assurance can be given that the investment objective will be achieved.

The figures provided that relate to past months or years and past performance cannot be relied on as a guide to future performance or construed as a reliable indicator as to future performance. Throughout this review, the citation of specific trades or strategies is intended to illustrate some of the investment methodologies and philosophies of Volta Finance, as implemented by BNPP AM. The historical success or BNPP AM’s belief in the future success, of any of these trades or strategies is not indicative of, and has no bearing on, future results.

The valuation of financial assets can vary significantly from the prices that the BNPP AM could obtain if it sought to liquidate the positions on behalf of the Volta Finance due to market conditions and general economic environment. Such valuations do not constitute a fairness or similar opinion and should not be regarded as such.

Editor: BNP PARIBAS ASSET MANAGEMENT Europe, a company incorporated under the laws of France, having its registered office located at 1 boulevard Haussmann – 75009 Paris, registered with the Paris Trade and Companies Register under number 319 378 832, and a Portfolio Management Company, holder of AMF approval no. GP 96002, issued on 19 April 1996.

*****

Attachment

• 2026.07.31 VFL – Annual Financial Report and Accounts Unsigned